Psilocybin for Eating Disorders: The Emerging Research

Eating disorders — particularly anorexia nervosa — have the highest mortality rate of any psychiatric condition. They are also among the most treatment-resistant. A significant minority of patients never recover with conventional treatment. Early psilocybin research is producing results in this population that conventional medicine has not been able to achieve.

Why eating disorders are so hard to treat

Eating disorders — particularly anorexia nervosa — present unique treatment challenges that most psychiatric conditions do not.

Ego-syntonic nature: Unlike depression or anxiety, which most patients experience as unwanted and distressing, anorexia is often ego-syntonic — the disorder aligns with the patient's sense of identity and self. The patient does not simply want to get better, because "better" involves abandoning beliefs and behaviors that feel central to who they are. This fundamentally complicates the therapeutic relationship.

Medical complexity: Malnutrition creates physiological conditions that affect cognitive function, emotional regulation, and therapeutic responsiveness. Severely underweight patients are in a state of medical emergency that must be addressed before meaningful psychological treatment can occur — yet psychological treatment is ultimately what's required for lasting recovery.

High relapse rates: Even among patients who achieve weight restoration through treatment, relapse rates are high. The psychological patterns underlying the disorder persist beyond weight restoration, creating ongoing vulnerability.

Standard treatment — cognitive-behavioral therapy, family-based therapy, nutritional rehabilitation, and sometimes medication — produces full recovery in approximately half of patients. For the other half, the options narrow and the prognosis worsens with time.

The early research

The most significant published pilot was conducted at Imperial College London and published in a peer-reviewed journal. Ten participants with anorexia nervosa received two psilocybin sessions in a therapeutic context. The results showed meaningful improvements in eating disorder symptoms across all participants, as measured by standardized anorexia assessment tools.

Participants also showed improvements in psychological flexibility, reductions in depression and anxiety, and changes in their relationship to food and body image that persisted beyond the acute experience.

The study was small — 10 participants, no control group — and does not constitute proof of efficacy. For a condition with the treatment resistance characteristics of anorexia, a signal of improvement across all participants in a pilot is significant enough to pursue systematically. Larger trials are now in development.

The mechanism — ego dissolution and body image

The central psychological feature of anorexia is a rigidly distorted relationship to body image — an inability to accurately perceive one's own body and a rigid attachment to extreme thinness as identity. This rigidity is, neurologically, a pattern of self-referential processing that is highly resistant to change through ordinary therapeutic means.

Psilocybin's most significant psychological effect is precisely the loosening of rigid self-referential processing — ego dissolution. The constructed sense of self, including the body image that has become central to anorexic identity, becomes temporarily permeable. Participants describe being able to see their body and their relationship to it from outside the disorder for the first time.

The default mode network (DMN) — the brain's self-referential system — maintains the rigid body image and identity patterns characteristic of anorexia. Psilocybin suppresses DMN activity and connectivity during the acute experience and produces persistent changes to DMN patterns afterward. These changes represent exactly what anorexia treatment needs: flexibility in the self-referential system that has become pathologically rigid.

What participants report

Qualitative accounts from Imperial College participants describe several consistent themes:

Seeing the disorder from outside: Multiple participants described being able to observe their eating disorder from a perspective that was not inside it — to see what the disorder was doing to them rather than through it. This perspective shift, which years of CBT often fails to produce, occurred within a single session.

Reduced body image distortion: Several participants reported that their perception of their own body changed during the experience — the distorted perception that characterizes anorexia temporarily resolved, allowing them to see their body more accurately.

Disruption of the identity-disorder fusion: The ego-syntonic nature of anorexia means the disorder has fused with identity. Ego dissolution — the temporary dissolution of the constructed self — appears to create space between the person and the disorder that was not previously accessible.

The perfectionism connection

Perfectionism — the rigid pursuit of unattainable standards — is among the most consistent psychological features of eating disorders. It is not limited to food and body; perfectionism in people with eating disorders tends to be pervasive, affecting all domains of life.

Psilocybin's effects on rigid, perfectionist thinking patterns may be directly relevant here. The compound produces a state of psychological flexibility, acceptance, and reduced attachment to specific outcomes that is the opposite of perfectionist rigidity. Several participants in eating disorder research specifically identified changes in their perfectionist thinking as a key therapeutic element.

Who this research applies to

The Imperial College pilot studied adults with anorexia nervosa. The evidence does not yet cover:

• Bulimia nervosa (separate condition, separate treatment profile)
• ARFID (avoidant/restrictive food intake disorder)
• Binge-eating disorder
• Adolescents (separate considerations apply)
• Patients who are medically unstable due to malnutrition

The research is specific to anorexia in medically stable adults. Extrapolation to other eating disorders requires its own dedicated investigation.

Medical contraindications specific to eating disorders

Eating disorders create specific physiological conditions that affect psychedelic safety:

Electrolyte abnormalities: Malnutrition and purging create electrolyte imbalances — particularly potassium and sodium — that affect cardiac function. Psilocybin produces cardiovascular changes (elevated heart rate, mild blood pressure changes) that require normal cardiac baseline. Medical clearance is specifically required.

Medication interactions: Many eating disorder patients are on psychiatric medications. Antidepressants, in particular, interact with psilocybin through serotonin receptor competition and require careful management.

Cognitive impairment from malnutrition: Significantly underweight patients have impaired cognitive function that affects therapeutic processing. Psilocybin-assisted therapy for eating disorders requires participants to be medically stabilized before sessions.

The Technospermia frame

From a Technospermia perspective, psilocybin's effect on eating disorders illustrates what may be the most fundamental function of consciousness technology: the loosening of the grip of the constructed self on self-destructive patterns.

Anorexia is the constructed self — specifically, the rigid self-narrative "I am a person who controls my body through restriction" — maintaining itself against the interests of the organism that hosts it. The disorder is, in a sense, the default mode network's self-referential processing functioning pathologically, prioritizing a constructed identity over survival.

A compound that temporarily dissolves the constructed self, creating space for the organism to perceive what it actually needs rather than what the disorder demands, is functioning at precisely the level where eating disorders are most intractable. Whether this represents the intended use of consciousness technology or an emergent discovery of its applications, the mechanistic fit is close.

Participants in the Imperial College anorexia study described the psilocybin experience as allowing them to see their body and their relationship to food from outside the disorder for the first time. One participant said: I saw that I was torturing myself and I couldn't understand why. The rigidity that had defined my relationship to my body just... wasn't there anymore. For a condition defined by that rigidity, that shift is significant.

Related reading: Psilocybin therapy research · What is ego dissolution? · Psychedelics and mental health · Harm reduction guide